Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) News
Latest headlines that mention RXRX, newest first · each headline opens the original publisher
- Last price
- $4.36
- Day change
- +10.38%
- Next earnings
- 2026-11-04
RXRX headlines
latest coverageAI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.
Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.
Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships.
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
The stock looks cheap, but appearances can be deceiving.
RXRX news alerts
Get an alert by email or push when a new headline mentions RXRX.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.